Radiation Oncology/RTOG Trials/7810


  • Title: Phase I/II Study of Half-Body Radiotherapy for Multiple Osseous Metastases
  • Objectives:
    • (1) Evaluate the frequency and the duration of pain relief as a function of the dose schedules proposed.
    • (2) Assess tumor and response by evaluation of measurable lesions in different sites.
    • (3) Determine the normal tissue tolerance and toxicity following single exposure doses of irradiation, particularly focusing on the dose-limiting organs: bone marrow, lung, kidney, liver, brain, spinal cord, small bowel and heart, both in terms of acute and late reactions and damage.
    • (4) Study the natural history of progression of disseminated cancer, particularly the osseous lesions, and develop a useful staging system for evaluation of disseminated disease.
  • NCI_Protocol: Dose escalation of hemibody irradiation
  • Enrolled: 168 patients
  • Conclusion:
    • PMID 2423225 -- Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report. (Salazar OM, Cancer 1986). Conclusion: "HBI achieves pain relief sooner and with less evidence of pain recurrence in the irradiated area than conventionally treated patients. The most effective and safest of the HBI doses tested were 600 rad for the upper HBI and 800 rad for the lower or mid-HBI."
  • Publications:
    • PMID 6178497 -- The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. (Tong D, Cancer 1982). Review.
    • PMID 6169699 -- Single-dose half-body irradiation for the palliation of multiple bone metastases from solid tumors: a preliminary report. (Salazar OM, IJRBOP 1981). No abstract.